5 Large-Cap Drug Stocks Well Poised To Beat On Q3 Earnings
Zacks Investment Research | Oct 13, 2017 04:14AM ET
The biotech industry has witnessed a great turnaround this year after the drug pricing issue crippled its performance last year. After declining 5.2% last year, the .
The Zacks Consensus Estimate for the third quarter is $1.03 per share. The company has a mixed earnings surprise record. In fact, Lilly’s earnings surpassed expectations in two of the last four quarters, with an average negative surprise of 0.89%.
Lilly is scheduled to report results on Oct 24.
Our next choice is Pfizer (NYSE:PFE), Inc. (GSK ) makes it to our list of likely outperformers in the third quarter by virtue of its Zacks Rank #3 and an Earnings ESP of +6.30%. The Zacks Consensus Estimate is pegged at 85 cents per share. Glaxo is expected to report its results on Oct 25.
Bottom Line
Challenges in the form of competitive and pricing pressure will remain. However, a number of companies in the healthcare space have fared well. Picking some outperformers from the space, backed by a solid Zacks Rank and a positive Earnings ESP, could lead investors to gain this earnings season.
4 Stocks to Watch after the Massive Equifax (NYSE:EFX) Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.